Geron Corp. (Nasdaq:GERN), which develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, said this morning that it received a milestone payment of $1.5 million from Exeter Life Sciences, Inc. for the final “risk assessment” released by the U.S. Food and Drug Administration addressing food products made from cloned animals or their progeny.  

Shares gained 4%, or $0.19, to $5.37 ahead of the opening bell. For detailed price information and recent news stories about Geron, click GERN.

For access to the full article, you must be a registered member - it's FREE.